Incanthera PLC (AQSE:INC) shares surged 21% to 1.7p after announcing an all-share acquisition of Swiss premium skincare brand Énielle and appointing Stuart Robertson as CEO. The deal gives overseas buyers and distributors a new combined skincare platform with clinical backing, signaling potential supply-chain opportunities in premium cosmeceuticals.
Deal structure and share issuance
The acquisition is funded entirely through the issuance of up to 54 million new ordinary shares at 2p each. Of these, 13.79 million shares will be admitted to trading on the Aquis Stock Exchange Growth Market around 10 June, while the remaining 40.21 million deferred shares are subject to sales performance criteria over six months. No cash changes hands beyond transaction costs.
Brand portfolio and product positioning
Énielle, based on lectin-derived bioactive protein formulations and supported by multiple clinical studies, has produced over 15,000 serum units in Switzerland in the past five years, with about 6,000 finished units ready for immediate sale. It joins Incanthera's existing Skin+CELL range to create a "protect by day, repair by night" routine, with Énielle as a daytime product and Skin+CELL as an evening cosmeceutical for cellular repair and UV damage protection.
Leadership changes and strategic direction
Stuart Robertson, majority shareholder of seller GIFFRIES Technology AG, becomes CEO effective immediately, taking charge of commercial leadership, pricing strategy, and profit and loss. Former CEO Simon Ward moves to chief scientific officer, overseeing clinical programs and regulatory positioning. Executive chairman Tim McCarthy steps down after 12 years, including leading the company's IPO. The company plans to appoint a non-executive chair.
Sourcing context and buyer signals
Incanthera intends to pursue a more aggressive multi-channel sales strategy, including direct-to-consumer, premium retail, and subscription models. Pricing is under review to reflect current market conditions, including US tariff regulations. A £250,000 convertible loan facility from Robertson will fund integration costs, with £100,000 drawn immediately. The acquisition benefits from approximately £3 million in prior investment in brand development and clinical research by previous owners.
Source: Read the original report | Published: June 04, 2026